Want to join the conversation?
$REGN 2Q15 Call: Based on the strong US EYLEA net sales in 2Q15, the company is increasing its full year US EYLEA net sales guidance to be YoverY growth of between 45-50% from the previously provided range of 30-35%. Recently announced a major collaboration with Sanofi in immuno-oncology.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.